The First Kilogram Synthesis of Beclabuvir, an HCV NS5B Polymerase Inhibitor

被引：35

作者：

Bien, Jeffrey ^{[1
]}

Davulcu, Akin ^{[1
]}

DelMonte, Albert J. ^{[1
]}

Fraunhoffer, Kenneth J. ^{[1
]}

Gao, Zhinong ^{[1
]}

Hang, Chao ^{[1
]}

Hsiao, Yi ^{[1
]}

Hu, Wenhao ^{[1
]}

Katipally, Kishta ^{[1
]}

Littke, Adam ^{[1
]}

Pedro, Aghogho ^{[1
]}

Qiu, Yuping ^{[1
]}

Sandoval, Maria ^{[1
]}

Schild, Richard ^{[1
]}

Soltani, Michelle ^{[1
]}

Tedesco, Anthony ^{[1
]}

Vanyo, Dale ^{[1
]}

Vemishetti, Purushotham ^{[1
]}

Waltermire, Robert E. ^{[1
]}

机构：

[1] Bristol Myers Squibb Co, Chem & Synthet Dev, One Squibb Dr,POB 191, New Brunswick, NJ 08903 USA

来源：

ORGANIC PROCESS RESEARCH & DEVELOPMENT | 2018年 / 22卷 / 10期

关键词：

asymmetric; cyclopropanation; direct arylation; palladium; rhodium; catalysis; HEPATITIS-C VIRUS; REDUCTIVE ALKYLATION; INDOLES; DISCOVERY; RECEPTOR;

D O I：

10.1021/acs.oprd.8b00214

中图分类号：

O69 [应用化学];

学科分类号：

081704 ;

摘要：

The process development and kilogram-scale synthesis of beclabuvir (BMS-791325, 1) is described. The convergent synthesis features the use of asymmetric catalysis to generate a chiral cyclopropane fragment and coupling with an indole fragment via an alkylation. Subsequent palladium-catalyzed intramolecular direct arylation efficiently builds the central seven-membered ring. The target was prepared in 12 linear steps with five isolations in an overall yield of 8%.

引用

页码：1393 / 1408

页数：16

共 50 条

[41] NS5B polymerase inhibitors in phase II clinical trials for HCV infection
Borgia, Guglielmo
Maraolo, Alberto Enrico
Nappa, Salvatore
Gentile, Ivan
Buonomo, Antonio Riccardo
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2018, 27 (03) : 243 - 250
[42] IMPACT OF ANTIRETROVIRAL THERAPY ON THE VARIABILITY OF THE HCV NS5B POLYMERASE IN HIV/HCV COINFECTED PATIENTS
Plaza, Z.
Soriano, V.
Bar-Magen, T.
Gonzalez, M. M.
Di Lello, F.
Macias, J.
Labarga, P.
Pineda, J. A.
Poveda, E.
JOURNAL OF HEPATOLOGY, 2011, 54 : S486 - S486
[43] Pyridine Carboxamides: Potent Palm Site Inhibitors of HCV NS5B Polymerase
Cheng, Cliff C.
Huang, Xiaohua
Shipps, Gerald W., Jr.
Wang, Yu-Sen
Wyss, Daniel F.
Soucy, Kyle A.
Jiang, Chuan-kui
Agrawal, Sony
Ferrari, Eric
He, Zhiqing
Huang, H-C
ACS MEDICINAL CHEMISTRY LETTERS, 2010, 1 (09): : 466 - 471
[44] Quantitative structure and bioactivity relationship study on HCV NS5B polymerase inhibitors
Wang, M.
Zhong, M.
Yan, A.
Li, L.
Yu, C.
SAR AND QSAR IN ENVIRONMENTAL RESEARCH, 2014, 25 (01) : 1 - 15
[45] Classification of HCV NS5B Polymerase Inhibitors Using Support Vector Machine
Wang, Maolin
Wang, Kai
Yan, Aixia
Yu, Changyuan
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2012, 13 (04) : 4033 - 4047
[46] Filibuvir, a non-nucleoside NS5B polymerase inhibitor for the potential oral treatment of chronic HCV infection
Beaulieu, Pierre L.
IDRUGS, 2010, 13 (12) : 938 - 948
[47] Discovery of new scaffolds for rational design of HCV NS5B polymerase inhibitors
Golub, Andriy G.
Gurukumar, K. R.
Basu, Amartya
Bdzhola, Volodymyr G.
Bilokin, Yaroslav
Yarmoluk, Sergiy M.
Lee, Jin-Ching
Talele, Tanaji T.
Nichols, Daniel B.
Kaushik-Basu, Neerja
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2012, 58 : 258 - 264
[48] Characterization of forced degradation products and in silico toxicity prediction of Sofosbuvir: A novel HCV NS5B polymerase inhibitor
Swain, Debasish
Samanthula, Gananadhamu
Bhagat, Shweta
Bharatam, P. V.
Akula, Venkatakrishna
Sinha, Barij N.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2016, 120 : 352 - 363
[49] Molecular Modeling Comparison of the Performance of NS5b Polymerase Inhibitor (PSI-7977) on Prevalent HCV Genotypes
Abdo A. Elfiky
Wael M. Elshemey
Wissam A. Gawad
Omar S. Desoky
The Protein Journal, 2013, 32 : 75 - 80
[50] Molecular Modeling Comparison of the Performance of NS5b Polymerase Inhibitor (PSI-7977) on Prevalent HCV Genotypes
Elfiky, Abdo A.
Elshemey, Wael M.
Gawad, Wissam A.
Desoky, Omar S.
PROTEIN JOURNAL, 2013, 32 (01): : 75 - 80

← 1 2 3 4 5 →